RBQM

May 2019

Centralized Monitoring: a Greater Advantage to a Broader Range of Trials

By |2019-05-07T09:37:52+00:00May 2, 2019|Blog, Infographic|0 Comments

Regulatory bodies are unanimous, today's clinical research needs Centralized Monitoring. We summarized Centralized Monitoring the infographic way, download your free copy here...

Mar 2019

15. DVMD-Fachtagung in Düsseldorf

By |2019-03-04T07:31:03+00:00March 5, 2019||Comments Off on 15. DVMD-Fachtagung in Düsseldorf

Die Fachtagungen des DVMD sind jedes Mal ein informativer Querschnitt aus allen relevanten Themen rund um Dokumentation und Informationsmanagement in der Medizin. Jede Fachtagung greift dabei immer ein Schwerpunktthema auf. In 2019 wird es der Einfluss der Digitalisierung auf die Medizin sein.

Sep 2018

3rd Annual Global Risk Based Monitoring Conference

By |2018-08-30T15:18:38+00:00September 13, 2018||Comments Off on 3rd Annual Global Risk Based Monitoring Conference

Sponsor, Speaker....and Many New Features to Demo With a surge of new technologies and trial models being implemented, the time is now to capitalise on industry expertise to capture the cost and efficiency benefits of risk-based monitoring. Join us in London for CBI’s 3rd annual Global [...]

Jul 2018

DIA 2018 Global Annual Meeting: was this year’s theme the most dead-on yet?

By |2018-07-17T09:10:07+00:00July 16, 2018|Blog|0 Comments

The dramatic expansion of prescription drug deaths inspired this year's theme "driving insights to action". Insights that could be deployed through novel disruptive technologies such as Risk-based Quality Management (RBQM). Cyntegrity's Johann Proeve and Nimita Limaye were in Boston and share their observations with us.

May 2018

Key Risk Indicators Reveal Blind Spots in Clinical Trials

By |2018-05-16T09:02:30+00:00May 15, 2018|Blog|0 Comments

By design, the traditional spot-checking type of audits leave a blind spot on systemic quality threats. Key Risk Indicators however, form the core of a widely applicable concept that captures all relevant risks in scope and provides project managers and QM experts targeted and objective updates on actionable issues and trends.

Dec 2014

Duality of Risk-based Monitoring Definition: EMA vs FDA

By |2019-03-21T12:16:18+00:00December 9, 2014|White Paper|Comments Off on Duality of Risk-based Monitoring Definition: EMA vs FDA

In October 2014 at the Risk-based Monitoring conference in Copenhagen the Senior Director QA Operations of Janssen, Jan Van Parijs said: "Industry is historically heavily regulated, so as an industry we are kind of used to the fact that the authorities provide a set [...]

Upcoming Events

Register Today!

Get Free Test Access